Trial Profile
The Time to Protection and Adherence Requirements of Raltegravir With or Without Lamivudine in Protection From HIV Infection
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 May 2021
Price :
$35
*
At a glance
- Drugs Lamivudine (Primary) ; Raltegravir (Primary)
- Indications HIV infections
- Focus Pharmacokinetics; Proof of concept
- Acronyms R-PrEP
- 14 May 2021 Results comparing the pharmacokinetics of raltegravir and lamivudine in genital tissue against ex vivo tissue infection with HIV-1, published in the Journal of Antimicrobial Chemotherapy
- 01 Apr 2020 Status has been changed to completed.
- 01 Apr 2020 Results assessing PK/PD study of Raltegravir alone or combined with Lamivudine as PrEP, published in the Internet Document